HIMS
xyz:
equity
· Hyperliquid
—
Equity perp — Hyperliquid synthetic derivative. For real-time exchange pricing, turn off the Crypto toggle and search the bare equity ticker.
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.
Mark Price
$17.30
24h Change
-3.46%
Funding (8h)
+0.0024%
Open Interest
87,051
24h Volume
$2.08M
Oracle Price
$17.30
Mark − Oracle
-0.0812%
Prev Day Close
$17.91
As of (UTC)
2026-11-19 10:14:29
Daily candles — last 91 days
Funding rate history — last 7 days (8h cycles)
Positive funding = longs paying shorts (long-crowded). Negative = shorts paying longs (short-crowded).
Peers — same category
| Coin | Mark | 24h % |
|---|---|---|
| NVDA | $153.51 | -4.82% |
| SKHX | $891.82 | +2.73% |
| SOXL | $53.63 | +0.99% |
| SNDK | $807.55 | -2.59% |
| ANT | $104.41 | +5.78% |
News headlines Yahoo Finance, 1h cache
-
Hims Is Getting into Peptides
2026-11-18 17:43 · Yahoo
-
Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health
2026-11-18 14:00 · Yahoo
-
Hims & Hers Stock Fell 32% As Profit Slipped
2026-11-17 14:13 · Yahoo
-
Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy?
2026-11-16 18:56 · Yahoo
-
Hims & Hers Lost 100K Subscribers Before Adding Eli Lilly’s $299 Zepbound: Buy the Dip, or Wait?
2026-11-16 09:28 · Yahoo
-
LifeStance, Private Equity Rollup Turned Organic Growth Stock, Targets A Profound Void
2026-11-13 21:19 · Yahoo
-
Should Hims & Hers Stock's Drop After Earnings Worry You?
2026-11-13 20:23 · Yahoo
-
Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?
2026-11-13 18:00 · Yahoo
-
HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs
2026-11-13 15:12 · Yahoo
-
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
2026-11-13 13:00 · Yahoo